These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16277882)

  • 1. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.
    García-Sáenz JA; Martín M; Puente J; López-Tarruella S; Casado A; Moreno F; Grande E; Díaz-Rubio E
    Clin Breast Cancer; 2005 Oct; 6(4):325-9. PubMed ID: 16277882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
    Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
    Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
    Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Rudas M; Mader RM; Gnant M; Zielinski CC; Steger GG
    J Clin Oncol; 2007 Sep; 25(25):3853-8. PubMed ID: 17679724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
    Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
    Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Onkologie; 2005 Nov; 28(11):582-6. PubMed ID: 16249644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
    Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
    Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
    Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?
    Esposito A; Munzone E; Bagnardi V; Adamoli L; Sciandivasci A; Cullurà D; Goldhirsch A; Nolè F
    Anticancer Drugs; 2012 Nov; 23(10):1089-98. PubMed ID: 22760210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Bayo-Calero JL; Mayordomo JI; Sánchez-Rovira P; Pérez-Carrión R; Illaramendi JJ; García-Bueno JM; González-Flores E; Crespo C; Ramos-Vázquez M; García-Palomo A; Ruiz-Borrego M; de la Haba J; Gómez-Bernal A; Yubero-Esteban A
    Clin Breast Cancer; 2008 Jun; 8(3):264-8. PubMed ID: 18650157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
    Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
    Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study).
    Adamo V; Franchina T; Adamo B; Ferraro G; Rossello R; Maugeri Saccà M; Scibilia C; Valerio MR; Russo A
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi11-5. PubMed ID: 17591801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.